These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38674108)

  • 61. Lymphocytes in Peritumoral Stroma: Evaluation in Epithelial Ovarian Neoplasms.
    Lima CA; Jammal MP; Etchebehere RM; Murta EFC; Nomelini RS
    Immunol Invest; 2020 May; 49(4):397-405. PubMed ID: 31298603
    [No Abstract]   [Full Text] [Related]  

  • 62. Metformin changes the immune microenvironment of colorectal cancer in patients with type 2 diabetes mellitus.
    Saito A; Kitayama J; Horie H; Koinuma K; Ohzawa H; Yamaguchi H; Kawahira H; Mimura T; Lefor AK; Sata N
    Cancer Sci; 2020 Nov; 111(11):4012-4020. PubMed ID: 32794612
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Biomarkers for checkpoint inhibitor therapy in mucinous epithelial ovarian cancer.
    Bartl T; Alberts A; Papadopoulos SC; Wolf A; Muellauer L; Hofstetter G; Grimm C; Cacsire Castillo-Tong D
    Int J Gynecol Cancer; 2023 Sep; 33(9):1419-1426. PubMed ID: 37094966
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer.
    Kesar N; Winkelmann R; Oppermann J; Ghanaati S; Martin D; Neumayer T; Balster S; Rödel C; Rödel F; von der Grün J; Balermpas P
    Oral Oncol; 2020 Dec; 111():104931. PubMed ID: 32736208
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.
    Rasmussen M; Lim K; Rambech E; Andersen MH; Svane IM; Andersen O; Jensen LH; Nilbert M; Therkildsen C
    Gynecol Oncol; 2021 Sep; 162(3):686-693. PubMed ID: 34275654
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics.
    Karpathiou G; Casteillo F; Giroult JB; Forest F; Fournel P; Monaya A; Froudarakis M; Dumollard JM; Prades JM; Peoc'h M
    Oncotarget; 2017 Mar; 8(12):19310-19322. PubMed ID: 28038471
    [TBL] [Abstract][Full Text] [Related]  

  • 67. An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.
    Bottai G; Raschioni C; Losurdo A; Di Tommaso L; Tinterri C; Torrisi R; Reis-Filho JS; Roncalli M; Sotiriou C; Santoro A; Mantovani A; Loi S; Santarpia L
    Breast Cancer Res; 2016 Dec; 18(1):121. PubMed ID: 27912781
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma.
    Morse CB; Toukatly MN; Kilgore MR; Agnew KJ; Bernards SS; Norquist BM; Pennington KP; Garcia RL; Liao JB; Swisher EM
    Gynecol Oncol; 2019 May; 153(2):217-222. PubMed ID: 30803719
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment.
    D'Angelo SP; Shoushtari AN; Agaram NP; Kuk D; Qin LX; Carvajal RD; Dickson MA; Gounder M; Keohan ML; Schwartz GK; Tap WD
    Hum Pathol; 2015 Mar; 46(3):357-65. PubMed ID: 25540867
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells.
    Owens GL; Price MJ; Cheadle EJ; Hawkins RE; Gilham DE; Edmondson RJ
    Cancer Immunol Immunother; 2018 Oct; 67(10):1519-1531. PubMed ID: 30039427
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients.
    Truxova I; Kasikova L; Hensler M; Skapa P; Laco J; Pecen L; Belicova L; Praznovec I; Halaska MJ; Brtnicky T; Salkova E; Rob L; Kodet R; Goc J; Sautes-Fridman C; Fridman WH; Ryska A; Galluzzi L; Spisek R; Fucikova J
    J Immunother Cancer; 2018 Dec; 6(1):139. PubMed ID: 30526667
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Association of intra-tumoral tumour-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio is an independent prognostic factor in non-small cell lung cancer.
    Dirican N; Karakaya YA; Gunes S; Daloglu FT; Dirican A
    Clin Respir J; 2017 Nov; 11(6):789-796. PubMed ID: 26619201
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cancer-associated fibroblasts-derived FMO2 as a biomarker of macrophage infiltration and prognosis in epithelial ovarian cancer.
    Yu S; Yang R; Xu T; Li X; Wu S; Zhang J
    Gynecol Oncol; 2022 Nov; 167(2):342-353. PubMed ID: 36114029
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Tumour Infiltrating Lymphocytes (TILs) and immune composition in breast cancer patients from Kenya: Spatial distributions and associations with risk factors and tumour characteristics.
    Sayed S; Koka H; Abubakar M; Gardner K; Salgado R; Moloo Z; Caban-Ureña AB; Rosen D; Castro P; Saleh M; Shaikh AJ; Shah J; Figueroa J; Makokha F; Ha HK; Wang Z; Magangane P; Naidoo R; Ngundo V; Yang XR; Govender D
    Breast Cancer Res Treat; 2023 Jun; 199(2):401-413. PubMed ID: 37010652
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma.
    Hagemann AR; Hagemann IS; Cadungog M; Hwang WT; Patel P; Lal P; Hammond R; Gimotty PA; Chu CS; Rubin SC; Birrer MJ; Powell DJ; Feldman MD; Coukos G
    Cancer Biol Ther; 2011 Aug; 12(4):367-77. PubMed ID: 21785280
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The peritoneal tumour microenvironment of high-grade serous ovarian cancer.
    Leinster DA; Kulbe H; Everitt G; Thompson R; Perretti M; Gavins FN; Cooper D; Gould D; Ennis DP; Lockley M; McNeish IA; Nourshargh S; Balkwill FR
    J Pathol; 2012 Jun; 227(2):136-45. PubMed ID: 22322968
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma.
    Montfort A; Barker-Clarke RJ; Piskorz AM; Supernat A; Moore L; Al-Khalidi S; Böhm S; Pharoah P; McDermott J; Balkwill FR; Brenton JD
    Br J Cancer; 2020 Jun; 122(12):1803-1810. PubMed ID: 32249277
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Nicotinamide N-methyltransferase overexpression may be associated with poor prognosis in ovarian cancer.
    Harmankaya İ; Akar S; Uğraş S; Güler AH; Ezveci H; Aydoğdu M; Çelik Ç
    J Obstet Gynaecol; 2021 Feb; 41(2):248-253. PubMed ID: 32285726
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Quantitative Analysis of Immune Infiltrates in Primary Melanoma.
    Gartrell RD; Marks DK; Hart TD; Li G; Davari DR; Wu A; Blake Z; Lu Y; Askin KN; Monod A; Esancy CL; Stack EC; Jia DT; Armenta PM; Fu Y; Izaki D; Taback B; Rabadan R; Kaufman HL; Drake CG; Horst BA; Saenger YM
    Cancer Immunol Res; 2018 Apr; 6(4):481-493. PubMed ID: 29467127
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma.
    Pretscher D; Distel LV; Grabenbauer GG; Wittlinger M; Buettner M; Niedobitek G
    BMC Cancer; 2009 Aug; 9():292. PubMed ID: 19698134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.